论文部分内容阅读
目的:观察经皮选择性肝动脉化疗栓塞术(TACE)联合复方苦参注射液治疗中、晚期原发性肝癌的临床疗效。方法:将64例原发性肝癌患者随机分为单纯TACE组(32例)和TACE联合复方苦参注射液组(32例),分析比较2组患者治疗前、后甲胎蛋白含量、肿瘤大小、Child-pugh分级、MELD评分及生活质量KPS评分的变化,跟踪随访患者生存期,比较2组的治疗效果。结果:TACE联合复方苦参注射液组临床疗效各方面均优于单纯TACE组(P<0.05),TACE联合复方苦参注射液组患者生存期高于单纯TACE组(P<0.05);TACE联合复方苦参组治疗后KPS评分升高幅度高于单纯TACE组(P<0.05);TACE联合复方苦参注射液组治疗后MELD评分、Child-pugh评分降低幅度均大于单纯TACE组(P<0.05);TACE联合复方苦参注射液组术后甲胎蛋白降低及肿瘤体积的减小比单纯TACE组明显(P<0.05)。TACE联合复方苦参注射液组治疗过程中未见严重不良反应。结论:TACE联合复方苦参注射液治疗原发性肝癌的临床疗效显著,可以减少TACE术后不良反应的发生。
Objective: To observe the clinical effect of transcatheter arterial chemoembolization (TACE) and compound Kushen injection in the treatment of middle and advanced primary liver cancer. Methods: Sixty-four patients with primary hepatocellular carcinoma were randomly divided into three groups: TACE alone (TACE group) and TACE plus compound Kushen injection (32 patients). The levels of alpha-fetoprotein, tumor size , Child-pugh grading, MELD score and quality of life KPS score, follow-up of patients with follow-up of survival, the treatment effect of two groups were compared. Results: The clinical efficacy of TACE combined with Compound Kushen Injection was superior to that of TACE only in all aspects (P <0.05). The survival rate of TACE combined with Compound Kushen Injection was higher than that of TACE alone (P <0.05) The KPS score of Compound Kushen Decoction group was higher than that of TACE alone group (P <0.05). The MELD score and Child-pugh score of TACE combined with Compound Kushen Injection Group were significantly higher than that of TACE alone group (P <0.05) ); TACE combined with compound Kushen injection group decreased postoperative alpha-fetoprotein and tumor volume reduction than TACE group was significantly (P <0.05). TACE combined with Compound Kushen injection group no serious adverse reactions in the course of treatment. Conclusion: TACE combined with Compound Kushen Injection for the treatment of primary liver cancer has a significant clinical effect, which can reduce the incidence of adverse reactions after TACE.